Irina Conboy and her team at UC Berkeley are working on the anti-aging cure.

The study, published in Oncotarget, details the experiments concerning a small molecule drug that has shown to reduce the process of aging through stem cell tests on mice. The discovery is being called the possible "fountain of youth."

Diseases which begin through aging, such as late-onset diabetes, Alzheimers, and Parkinsons, are responsible for millions of deaths per year, and in turn the treatment options cost exorbitant amounts. By slowing down the aging process, Conboy and her colleagues believe they will be able to give people more options for their own wellbeing later in life, and save patients, hospitals, and taxpayers large sums of money.

The drug is known as the Alk5 kinase inhibitor which specifically attacks the TGF-beta1 pathway. This pathway as it ages begins to produce too much of itself, leading to the depletion of other pathways in the hippocampus.

The drug would not get rid of the pathway, which has its own intended benefits such as differentiating tissues, but rather regulate it so that it doesn't overproduce and allow for more stem cell growth.

The Alk5 kinase inhibitor could potentially hit the market in the form a shot in the near future. The only thing halting its release is the severe lack of funding in the sciences.

Fortunately, alternative sources of funding are coming from many tech giants, such as PayPal founder Peter Thiel and Calico, Google's anti-aging research project. 

Developers and supporters alike hope that with significant advances in the technology of anti-aging, death will come through more sudden, natural causes rather than prolonged, painful disease.

Cover image: Seattle Organic Restaurants